{"id":"https://openalex.org/W2017546723","doi":"https://doi.org/10.1159/000066203","title":"Perspectives on Anti-HER Monoclonal Antibodies","display_name":"Perspectives on Anti-HER Monoclonal Antibodies","alternate_titles":[],"publication_year":2002,"publication_date":"2002-11-13","ids":{"openalex":"https://openalex.org/W2017546723","doi":"https://doi.org/10.1159/000066203","mag":"2017546723","pmid":"https://pubmed.ncbi.nlm.nih.gov/12422051"},"language":"en","primary_location":{"id":"doi:10.1159/000066203","doi":"https://doi.org/10.1159/000066203","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000066203","pdf_url":null,"source":{"id":"https://openalex.org/S198727964","display_name":"Oncology","issn_l":"0030-2414","issn":["0030-2414","1423-0232"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2017546723"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055792960","display_name":"Malcolm Ranson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Malcolm Ranson","raw_affiliation_strings":["Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. malcolm.ransom@man.ac.uk","Medical Oncology, Christie Hospital, Manchester, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. malcolm.ransom@man.ac.uk","institution_ids":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]},{"raw_affiliation_string":"Medical Oncology, Christie Hospital, Manchester, UK","institution_ids":["https://openalex.org/I4210131968"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5114046059","display_name":"Mark X. Sliwkowski","orcid":"https://orcid.org/0009-0001-3656-3142","observed_orcids":["https://orcid.org/0009-0001-3656-3142"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mark X. Sliwkowski","raw_affiliation_strings":["Department of Molecular Oncology, Genentech Inc., San Francisco, Calif., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular Oncology, Genentech Inc., San Francisco, Calif., USA","institution_ids":["https://openalex.org/I183934855"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.6513,"has_fulltext":false,"cited_by_count":70,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.95018126,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":96},"biblio":{"volume":"63","issue":"Suppl. 1","first_page":"17","last_page":"24"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.9049999713897705},{"id":"https://openalex.org/keywords/egf-receptor","display_name":"EGF receptor","score":0.9399999976158142},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.7789999842643738},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/her2-dimerization","display_name":"HER2 dimerization","score":0.671999990940094},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8880000114440918},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.7590000033378601},{"id":"https://openalex.org/keywords/chimeric-monoclonal-antibody","display_name":"chimeric monoclonal antibody","score":0.875},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.7379999756813049},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.734000027179718}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.8854609727859497},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.8306249976158142},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.8304213285446167},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6142152547836304},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.5346523523330688},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4622388184070587},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4616149663925171},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4412177801132202},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43068695068359375},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4199264645576477},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4003511667251587},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3723721504211426},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3377954959869385},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.33501169085502625},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2699980139732361}],"mesh":[{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008024","descriptor_name":"Ligands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008453","descriptor_name":"Maytansine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008956","descriptor_name":"Models, Chemical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1159/000066203","doi":"https://doi.org/10.1159/000066203","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000066203","pdf_url":null,"source":{"id":"https://openalex.org/S198727964","display_name":"Oncology","issn_l":"0030-2414","issn":["0030-2414","1423-0232"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology","raw_type":"journal-article"},{"id":"pmid:12422051","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12422051","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology","raw_type":"Journal Article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/972736aa-3306-4d47-8cad-86676e999b00","doi":null,"is_oa":false,"landing_page_url":"https://research.manchester.ac.uk/en/publications/972736aa-3306-4d47-8cad-86676e999b00","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ranson, M & Sliwkowski, M X 2002, 'Perspectives on anti-HER monoclonal antibodies.', Oncology, vol. 63, pp. 17-24.","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W173357120","https://openalex.org/W1855853533","https://openalex.org/W1913074237","https://openalex.org/W1931708823","https://openalex.org/W1939364580","https://openalex.org/W1957565841","https://openalex.org/W1963974943","https://openalex.org/W1970341069","https://openalex.org/W1988435763","https://openalex.org/W1989673664","https://openalex.org/W2005204942","https://openalex.org/W2008249862","https://openalex.org/W2023660230","https://openalex.org/W2034185792","https://openalex.org/W2045844137","https://openalex.org/W2046737947","https://openalex.org/W2057458801","https://openalex.org/W2064047613","https://openalex.org/W2073051869","https://openalex.org/W2107981645","https://openalex.org/W2156670712","https://openalex.org/W2167358710","https://openalex.org/W2167531081","https://openalex.org/W2169434055","https://openalex.org/W2318605753","https://openalex.org/W2331348829","https://openalex.org/W2414321375","https://openalex.org/W2415032506"],"related_works":["https://openalex.org/W2163332468","https://openalex.org/W1968088171","https://openalex.org/W2769847998","https://openalex.org/W7222527430","https://openalex.org/W2416133349","https://openalex.org/W1031904433","https://openalex.org/W2278503843","https://openalex.org/W2493871616","https://openalex.org/W2764091212","https://openalex.org/W4240337536"],"abstract_inverted_index":{"The":[0],"ability":[1],"of":[2,17,50,62,86,112,126,140,181,199,218],"Herceptin":[3],"to":[4,46,108,115,122,132,191,203],"prolong":[5],"survival":[6],"in":[7,94,170],"women":[8],"with":[9,183,215],"HER2-overexpressing":[10],"breast":[11],"tumors":[12],"has":[13],"proven":[14],"the":[15,54,63,110,124,138,179,189],"concept":[16],"using":[18,113],"humanized":[19],"or":[20],"chimeric":[21],"monoclonal":[22],"antibodies":[23],"(MAbs)":[24],"for":[25,35,58,162,213],"cancer":[26],"therapy.":[27],"MAbs":[28,76,114,176],"have":[29,77,188],"been":[30,78],"developed":[31],"that":[32,80,153,155,177,207],"are":[33,60,81,105],"specific":[34],"many":[36],"tumorigenic":[37],"molecules":[38],"and":[39,73,103,166],"receptors.":[40],"They":[41],"can":[42],"potentially":[43],"be":[44,192],"used":[45],"treat":[47],"a":[48,100,133,144,159,216],"range":[49,217],"solid":[51,219],"tumors.":[52,220],"Among":[53],"most":[55],"promising":[56],"targets":[57],"therapy":[59,142,206],"members":[61,187],"human":[64],"epidermal":[65],"growth":[66],"factor":[67],"receptor":[68],"(HER/ErbB)":[69],"family,":[70],"particularly":[71],"HER1":[72],"HER2.":[74],"Several":[75],"produced":[79],"directed":[82],"against":[83],"HER1.":[84],"One":[85,119],"these":[87,200],"agents,":[88],"cetuximab":[89],"(Erbitux),":[90],"is":[91,98,149,168],"now":[92],"advanced":[93],"clinical":[95],"development.":[96],"HER2":[97,156,182],"also":[99],"key":[101],"target":[102],"methods":[104],"being":[106],"investigated":[107],"maximize":[109],"effect":[111],"inhibit":[116,178],"this":[117],"receptor.":[118],"approach":[120],"aims":[121],"augment":[123],"efficacy":[125],"trastuzumab":[127],"(Herceptin)":[128],"by":[129],"coupling":[130],"it":[131],"chemotherapeutic":[134],"agent,":[135],"thus":[136],"enabling":[137],"delivery":[139],"cytotoxic":[141],"at":[143],"cellular":[145],"level.":[146],"Another":[147],"opportunity":[148],"based":[150],"on":[151],"research":[152],"shows":[154],"acts":[157],"as":[158],"dimerization":[160],"partner":[161],"other":[163,184],"HER":[164,185],"receptors":[165],"consequently":[167],"important":[169],"HER-ligand-dependent":[171],"tumor":[172],"growth.":[173],"Therefore,":[174],"anti-HER2":[175],"association":[180],"family":[186],"potential":[190],"highly":[193],"effective.":[194],"This":[195],"article":[196],"reviews":[197],"some":[198],"alternative":[201],"approaches":[202],"MAb-based":[204],"anti-HER":[205],"will":[208],"hopefully":[209],"improve":[210],"treatment":[211],"outcome":[212],"patients":[214]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2017546723","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
